Screener
Castle Biosciences CSTL Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $63,764 | $116,729 |
| Marketable investment securities | 197,921 | 182,776 |
| Accounts receivable, net | 42,264 | 43,382 |
| Inventory | 10,461 | 10,254 |
| Prepaid expenses and other current assets | 14,491 | 7,956 |
| Total current assets | 328,901 | 361,097 |
| Long-term accounts receivable, net | 1,921 | 1,878 |
| Property and equipment, net | 100,934 | 97,443 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's inventories?
- Castle Biosciences (CSTL) reported inventories of $10.46M in Q1 2026.
- How has Castle Biosciences's inventories changed year-over-year?
- Castle Biosciences's inventories increased by 52.7% year-over-year, from $6.85M to $10.46M.
- What is the long-term trend for Castle Biosciences's inventories?
- Over 5 years (2020 to 2025), Castle Biosciences's inventories has grown at a 35.8% compound annual growth rate (CAGR), from $2.22M to $10.25M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Castle Biosciences's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude